Survival With Patients Treated With Salivary Gland Cancer

Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Salivary Gland Cancer Head and Neck Neoplasms Mouth Diseases Mouth Neoplasms Neoplasms Neoplasms by Site Salivary Gland Diseases Salivary Gland Neoplasms Stomatognathic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinic for maxillofacial surgery Clinical center of Vojvodina

Novi Sad, 11000, Serbia

About this study

The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996. to 31. December 2021. Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with salivary gland malignancies treted in the Clinic for maxillofacial surgery

Exclusion criteria

Incomplete medical data Patients with metastatic tumord of salivary gland Patients with recurrent malignancies of salivary glands sent from other clinics

Treatment and study plan

Surgical intervention with or without postoperative adjuvant therapy

Procedure

Surgical intervention with or without postoperative adjuvant therapy

Primary outcomes

Patients survival

Time frame: Through study completion, an average of 1 year

Survival of patients treated due to SGC during observation period of minimum 2 years

Sponsors and collaborators

Lead sponsor

Clinical Center of Vojvodina

Other

Registry information

Official study title

Prognostic Factors for Survival of Patients With Salivary Gland Malignancies

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: May 25, 2022
Registry last updated: May 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed